Ono Pharmaceutical is paying Biohaven $80 million upfront for regional rights to three IgG degraders across Japan, South Korea, Taiwan and members of the Association of Southeast Asian Nations. The package is led by BHV-1300, a phase 3 Graves’ disease candidate, and also includes a $20 million milestone payment plus a 20% cut of profits from sales in the licensed territories.
The deal gives Ono a late-stage immunology asset and two next-generation follow-ons without taking on global rights. For Biohaven, it is an early commercial validation point for a degrader platform the company continued backing after scaling back its R&D ambitions in March.
The assets in the deal
BHV-1300 is a protein degrader designed to selectively target IgG1, 2 and 4 while sparing IgG3. Biohaven said in January that data suggested a patient with Graves’ disease who received the IgG MoDE degrader had experienced complete suppression of disease-causing TSH receptor-stimulating antibodies. The company also describes BHV-1300 as suitable for self-administration through a “patient-friendly autoinjector.”
The Ono agreement also covers BHV-1310 and BHV-1320, which Biohaven describes as next-generation follow-on degraders. All three candidates originated in the Spiegel Lab at Yale University.
Why the deal matters
This is a regional transaction rather than a full-company platform bet, but it still signals where capital is concentrating: programs with differentiated mechanisms that have already shown enough biomarker or clinical traction to support territory-by-territory licensing. Biohaven CEO Vlad Coric called it “the first regional collaboration for an extracellular protein degrader.”
The timing is notable for both sides. Biohaven kept extracellular protein degraders as one of three areas it chose to persevere with after its March retrenchment. William Blair analysts said at the time that investors were focused on the degrader programs, citing “promising” early biomarker activity for the TRAP degrader BHV-1400 in IgA nephropathy.
For Ono, the license extends an immunology and inflammation buildout that Chief Operating Officer Toichi Takino described as “one of Ono's key focus areas.” The company already has bifunctional fusion proteins licensed from Shattuck Labs in a $227 million biobucks deal in 2024, bispecific antibodies developed in-house for autoimmune disease, and regional rights to Vertex Pharmaceuticals’ IgA nephropathy prospect povetacicept, which is awaiting an approval decision from the FDA.
Taken together, the Biohaven deal looks less like a one-off licensing move than a pattern: Ono is using regional deals to assemble an immunology portfolio with a mix of late-stage and next-generation mechanisms.
